Double-boosted protease inhibitor antiretroviral regimens: what role?

摘要: Despite the clinical benefit observed with early highly active antiretroviral therapy, its toxicity and inconvenience, strategy of sequentially adding newly available drugs to failing regimens meant that for many patients, it was difficult build an effective regimen soon after starting therapy. In this setting, idea using double-boosted protease inhibitors (PIs) a potent emerged. The rationale simultaneous use two PIs is (i) provide synergistic or additive activity against HIV; (ii) achieve higher plasma concentrations both only one booster; (iii) increase genetic barrier resistance; and/or (iv) avoid nucleoside reverse transcriptase inhibitor-sparing regimens.